Abstract:(Mol Ther. 22, 1333–1341; July 2014) The authors have discovered that the original article has errors in Figures 4, S1, and S2 that were introduced when a graduate student used the wrong shared image folder when putting together the figures. In the original Figure 4a, which shows expression of dystrophin-positive fibers in body-wide muscles, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4a now appears below. In the original Figure 4d, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4d now appears below. In the original Figure S1a, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure S1a now appears below. In the original Figures S2a and S2b, a note should be added to the figure legend: the representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a, and the representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. The corrected legend appears below. These corrections do not change the conclusions of the paper. The authors apologize for the errors and any confusion they may have caused.Figure 4dFunctional and phenotypic correction in mdx mice following treatment with M12–PMO conjugates at a single dose of 75 mg/kg intravenouslyView Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S1aFunctional evaluation of skeletal muscles following treatment with M12–PMO conjugates with 3 weekly injections at the dose of 25 mg/kg in mdx miceView Large Image Figure ViewerDownload Hi-res image Download (PPT) Figure S2. Histological and immunological measurement of potential toxicity in mdx mice treated with the M12–PMO conjugate with 3 weekly injections at 25 mg/kgThe representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a. The representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide–Morpholino Conjugate in Dystrophin-Deficient mdx MiceGao et al.Molecular TherapyJuly, 2014In BriefAntisense oligonucleotide (AO)–mediated splice correction therapy for Duchenne muscular dystrophy has shown huge promise from recent phase 2b clinical trials, however high doses and costs are required and targeted delivery can lower both of these. We have previously demonstrated the feasibility of targeted delivery of AOs by conjugating a chimeric peptide, consisting of a muscle-specific peptide and a cell-penetrating peptide, to AOs in mdx mice. Although increased uptake in muscle was observed, the majority of peptide–AO conjugate was found in the liver. Full-Text PDF Open Archive

Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development

Self‐Assembled Antibody‐Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides

Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)

Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle

Functional Rescue of Dystrophin-Deficient Mdx Mice by a Chimeric Peptide-PMO

Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-siRNA Conjugates for Drug Development

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model

High Antitumor Activity of Sortase A-generated Anti-Cd20 Antibody Fragment Drug Conjugates

Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy

Mdx mice dosed with antisense to CD49d and dystrophin exon skip morpholino; reduced force loss and affected gene expression pathways support ATL1102 combination therapy in DMD patients

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient Mdx Mice

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient <i>mdx</i> Mice (vol 22, pg 1333, 2014)

Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives

In Vitro Evaluation of Novel Antisense Oligonucleotides is Predictive of in Vivo Exon Skipping Activity for Duchenne Muscular Dystrophy

Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins

The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy

MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice

Organic-Solvent-Free "Lego-Like" Modular Preparation of Fab-Nondestructive Antibody-Drug Conjugates with Ultrahigh Drug-to-Antibody Ratio

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice

Evaluation of a new antisense oligonucleotide chemistry-2′-O-Methoxyethyl in Duchenne muscular dystrophy in vitro